In hepatocellular carcinoma, Itabashi et al. [132] firstly reported the suppression of angiotensin II-induced cell proliferation by targeting the AngII–EGFR cross-talk signaling mediated by ADAM9 and ADAM17. Here, ADAM9 is linked to hepatocellular carcinoma.